Pierrick Gj Fournier

List of Publications by Year
in descending order

36	2,665	361296 20	477173 29
papers	citations	h-index	g-index

37	37	37	3828
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transforming growth factor-Î² and its signaling pathway in skeletal complications of malignancy. , 2022, , 253-273.		0
2	Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes. Beilstein Journal of Nanotechnology, 2020, 11, 372-382.	1.5	34
3	TIE2 Induces Breast Cancer Cell Dormancy and Inhibits the Development of Osteolytic Bone Metastases. Cancers, 2020, 12, 868.	1.7	9
4	Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers, 2020, 12, 1014.	1.7	19
5	TGF-Î² and BMP Signaling Pathways in Cancer and Bone: In Sickness and in Health. , 2020, , 281-293.		0
6	Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. Journal of Bone and Mineral Research, 2020, 37, 1446-1463.	3.1	11
7	Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy. Journal of Nanobiotechnology, 2018, 16, 19.	4.2	31
8	Functionalized rare earth-doped nanoparticles for breast cancer nanodiagnostic using fluorescence and CT imaging. Journal of Nanobiotechnology, 2018, 16, 26.	4.2	32
9	In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization. Oncotarget, 2018, 9, 28016-28029.	0.8	4
10	The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget, 2017, 8, 26687-26701.	0.8	22
11	Halofuginone inhibits TGF-Î²/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget, 2017, 8, 86447-86462.	0.8	35
12	TGFÎ²-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. BoneKEy Reports, 2015, 4, 719.	2.7	17
13	The TGF-Î² Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell, 2015, 27, 809-821.	7.7	169
14	Tumorâ€“bone interactions: there is no place like bone. , 2015, , 13-28.		0
15	FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget, 2015, 6, 19647-19660.	0.8	38
16	Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases. Cancer Research, 2012, 72, 6247-6256.	0.4	66
17	Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone, 2011, 48, 259-266.	1.4	81
18	TGF-Î²-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Research, 2011, 71, 175-184.	0.4	203

#	Article	IF	Citations
19	Tumor-Bone Cell Interactions in Bone Metastases. , 2010, , 9-40.		1
20	GLI2-Mediated Melanoma Invasion and Metastasis. Journal of the National Cancer Institute, 2010, 102, 1148-1159.	3.0	149
21	How Do Bisphosphonates Inhibit Bone Metastasis In Vivo. Neoplasia, 2010, 12, 571-578.	2.3	59
22	Agents Targeting Prostate Cancer Bone Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1079-1088.	0.9	5
23	Hypoxia and TGF-Î² Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment. PLoS ONE, 2009, 4, e6896.	1.1	189
24	P16. Hypoxia and breast cancer bone metastasis: HIF-1Î± enhances TGF-Î² signaling and expression of prometastatic factors CXCR4 and VEGF. Cancer Treatment Reviews, 2008, 34, 18.	3.4	0
25	P32. Transforming growth factor-Î² (TGF-Î²) promotes prostate cancer bone metastases: Increased expression of pro-osteolytic genes and of PMEPA1, a new TGF-Î² signalling regulator. Cancer Treatment Reviews, 2008, 34, 25.	3.4	0
26	P48. Transforming growth factor Î² receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases. Cancer Treatment Reviews, 2008, 34, 37-38.	3.4	1
27	P57. Manipulating the bone mineral affinity of bisphosphonates to directly target cancer cells in the bone marrow. Cancer Treatment Reviews, 2008, 34, 42.	3.4	0
28	Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo. Cancer Research, 2008, 68, 8945-8953.	0.4	42
29	Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis. Cancer Research, 2007, 67, 2317-2324.	0.4	187
30	BMP7: A New Bone Metastases Prevention?. American Journal of Pathology, 2007, 171, 739-743.	1.9	5
31	Molecular Biology of Bone Metastasis. Molecular Cancer Therapeutics, 2007, 6, 2609-2617.	1.9	405
32	New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology, 2006, 18, 396-404.	2.0	52
33	Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity: Figure 1.. Cancer Research, 2005, 65, 4971-4974.	0.4	217
34	Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity. Journal of Biological Chemistry, 2003, 278, 45826-45832.	1.6	81
35	In Vitro and In Vivo Antitumor Effects of Bisphosphonates. Current Medicinal Chemistry, 2003, 10, 173-180.	1.2	80
36	Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research, 2002, 62, 6538-44.	0.4	421